🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Relay Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and Ireland registers with Relay Therapeutics as lead sponsor. Synced 26 Sep 2026
4Current trials
4Recruiting now
6Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Relay Therapeutics is the lead sponsor of 4 current clinical trials in our USA, UK and Ireland registers. 4 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Fulvestrant, RLY-2608 and Capivasertib. The most-studied condition is PIK3CA Mutation.

ClinicalTrials.gov trials by status

  • Recruiting4100%

Trials by phase

  • Phase 1250%
  • Phase 2125%
  • Phase 3125%
01

Clinical trials sponsored by Relay Therapeutics

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913 · ClinicalTrials.gov ↗ · PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations
Drug: RLY-2608
Phase 2 Recruiting 2025-06 Ireland, UK, USA
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521 · ClinicalTrials.gov ↗ · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor
Phase 3 Recruiting 2025-08 UK, USA
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226 · ClinicalTrials.gov ↗ · Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation
Phase 1 Recruiting 2026-03 USA
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432 · ClinicalTrials.gov ↗ · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer
Phase 1 Recruiting 2021-12 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Relay Therapeutics trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Relay Therapeutics trials

13 conditions
PIK3CA Mutation3Breast Cancer2PIK3CA-Related Overgrowth Spectrum (PROS)1Lymphatic Malformations1Vascular Malformations1HER2- Negative Breast Cancer1Hormone Receptor Positive Tumor1Advanced NRAS-Mutant Melanoma1Advanced NRAS-Mutant Solid Tumors1NRAS Mutation1NRAS G12D1Solid Tumor, Adult1HER2-negative Breast Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA44
Clinical trials in UK22
Clinical trials in Ireland11

A trial with sites in more than one country appears in each of those registers.

05

Questions about Relay Therapeutics trials

How many clinical trials does Relay Therapeutics sponsor?

Relay Therapeutics is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA, UK and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Relay Therapeutics trials recruiting?

Yes. 4 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Relay Therapeutics testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Fulvestrant (2), RLY-2608 (2), Capivasertib (1), PF-07220060 (1) and Palbociclib (1). The number in brackets is how many of its trials name each drug.

Does Relay Therapeutics have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.